 Rebecca Schweppe
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 22 | 2023 | 278 | 8.010 |
Why?
| | Proto-Oncogene Proteins B-raf | 10 | 2023 | 202 | 3.280 |
Why?
| | Thyroid Carcinoma, Anaplastic | 5 | 2023 | 37 | 2.590 |
Why?
| | src-Family Kinases | 4 | 2023 | 90 | 2.460 |
Why?
| | MAP Kinase Signaling System | 4 | 2023 | 292 | 1.640 |
Why?
| | Adenocarcinoma, Follicular | 4 | 2019 | 35 | 1.570 |
Why?
| | Focal Adhesion Kinase 1 | 4 | 2018 | 28 | 1.490 |
Why?
| | Dasatinib | 5 | 2023 | 46 | 1.290 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2021 | 67 | 1.140 |
Why?
| | Mutation | 10 | 2019 | 3457 | 1.120 |
Why?
| | Cell Line, Tumor | 18 | 2023 | 2851 | 1.070 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 671 | 0.990 |
Why?
| | Cell Culture Techniques | 4 | 2019 | 356 | 0.870 |
Why?
| | Protein Kinase Inhibitors | 6 | 2023 | 811 | 0.860 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 32 | 0.810 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 37 | 0.800 |
Why?
| | Neoplasm Transplantation | 5 | 2019 | 245 | 0.760 |
Why?
| | DNA, Neoplasm | 2 | 2013 | 154 | 0.750 |
Why?
| | Carcinoma | 3 | 2009 | 204 | 0.690 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 5 | 0.680 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 46 | 0.670 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 237 | 0.660 |
Why?
| | Thyroid Diseases | 1 | 2018 | 30 | 0.660 |
Why?
| | Ethics, Research | 1 | 2018 | 31 | 0.660 |
Why?
| | Prolactin | 4 | 2003 | 96 | 0.620 |
Why?
| | Endocrinology | 1 | 2018 | 68 | 0.620 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 401 | 0.620 |
Why?
| | Neoplasm Metastasis | 4 | 2016 | 544 | 0.620 |
Why?
| | Melanoma | 3 | 2021 | 664 | 0.610 |
Why?
| | Telomerase | 2 | 2019 | 207 | 0.610 |
Why?
| | Mice, Nude | 7 | 2021 | 663 | 0.600 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 181 | 0.590 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2019 | 407 | 0.560 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 1974 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 455 | 0.510 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1597 | 0.500 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1059 | 0.480 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1390 | 0.460 |
Why?
| | Carcinoma, Papillary | 2 | 2014 | 76 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 2062 | 0.440 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1167 | 0.440 |
Why?
| | Disease Models, Animal | 4 | 2019 | 3730 | 0.440 |
Why?
| | Cell Proliferation | 7 | 2021 | 2275 | 0.420 |
Why?
| | Thiazoles | 1 | 2012 | 121 | 0.410 |
Why?
| | DNA-Binding Proteins | 6 | 2014 | 1346 | 0.390 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 740 | 0.370 |
Why?
| | Bone Neoplasms | 1 | 2012 | 199 | 0.360 |
Why?
| | Promoter Regions, Genetic | 6 | 2018 | 1158 | 0.360 |
Why?
| | Humans | 32 | 2023 | 118974 | 0.360 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 27 | 0.350 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1965 | 0.350 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 12 | 0.350 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 874 | 0.350 |
Why?
| | Animals | 19 | 2021 | 33381 | 0.340 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 26 | 0.340 |
Why?
| | Pyrimidines | 1 | 2012 | 382 | 0.340 |
Why?
| | Iodine Radioisotopes | 2 | 2023 | 130 | 0.340 |
Why?
| | Protein Processing, Post-Translational | 3 | 2012 | 408 | 0.320 |
Why?
| | Mice | 10 | 2021 | 15520 | 0.320 |
Why?
| | Benzodioxoles | 1 | 2009 | 84 | 0.320 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 173 | 0.310 |
Why?
| | Proto-Oncogene Proteins | 3 | 2003 | 618 | 0.310 |
Why?
| | Cell Differentiation | 2 | 2014 | 1753 | 0.310 |
Why?
| | Signal Transduction | 8 | 2018 | 4709 | 0.310 |
Why?
| | Transcription Factors | 5 | 2014 | 1570 | 0.310 |
Why?
| | Quinazolines | 1 | 2009 | 245 | 0.300 |
Why?
| | Cell Line | 5 | 2019 | 2707 | 0.300 |
Why?
| | Heterografts | 3 | 2016 | 130 | 0.290 |
Why?
| | Apoptosis | 4 | 2021 | 2484 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 14 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 154 | 0.270 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 290 | 0.250 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 246 | 0.250 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 31 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 80 | 0.230 |
Why?
| | Phenotype | 2 | 2023 | 3003 | 0.220 |
Why?
| | Fibronectins | 1 | 2023 | 114 | 0.220 |
Why?
| | Phosphorylation | 7 | 2015 | 1633 | 0.210 |
Why?
| | Models, Biological | 2 | 2020 | 1715 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2023 | 420 | 0.200 |
Why?
| | Mass Spectrometry | 2 | 2009 | 681 | 0.200 |
Why?
| | Pyrimidinones | 1 | 2021 | 86 | 0.190 |
Why?
| | Aminopyridines | 1 | 2021 | 85 | 0.190 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2020 | 160 | 0.190 |
Why?
| | Pyridones | 1 | 2021 | 119 | 0.190 |
Why?
| | Pyrroles | 1 | 2021 | 191 | 0.190 |
Why?
| | Proteins | 2 | 2003 | 938 | 0.180 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 21 | 0.170 |
Why?
| | Piperazines | 1 | 2021 | 316 | 0.170 |
Why?
| | Ethics Consultation | 1 | 2018 | 6 | 0.170 |
Why?
| | Ethics, Professional | 1 | 2018 | 15 | 0.170 |
Why?
| | Professional Misconduct | 1 | 2018 | 11 | 0.170 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 44 | 0.160 |
Why?
| | Publications | 1 | 2018 | 42 | 0.160 |
Why?
| | NF-kappa B | 2 | 2014 | 670 | 0.160 |
Why?
| | Adrenal Cortex | 1 | 2018 | 34 | 0.160 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 46 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2020 | 331 | 0.160 |
Why?
| | Pyridines | 1 | 2021 | 440 | 0.160 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 31 | 0.150 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 91 | 0.150 |
Why?
| | Genomics | 2 | 2020 | 706 | 0.150 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 48 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2006 | 2445 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 2018 | 47 | 0.150 |
Why?
| | Cell Growth Processes | 1 | 2016 | 54 | 0.140 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 175 | 0.140 |
Why?
| | Genes, ras | 1 | 2016 | 95 | 0.140 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 54 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 453 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2018 | 422 | 0.140 |
Why?
| | Disease Management | 1 | 2020 | 571 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-yes | 1 | 2015 | 2 | 0.130 |
Why?
| | Female | 6 | 2021 | 61565 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2016 | 253 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2016 | 182 | 0.130 |
Why?
| | Heart Neoplasms | 1 | 2015 | 50 | 0.130 |
Why?
| | Cell Death | 1 | 2016 | 339 | 0.120 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2014 | 8 | 0.120 |
Why?
| | Thyroid Gland | 1 | 2014 | 84 | 0.120 |
Why?
| | Data Collection | 1 | 2016 | 658 | 0.110 |
Why?
| | Binding Sites | 3 | 2003 | 1224 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 249 | 0.110 |
Why?
| | Sirolimus | 1 | 2014 | 195 | 0.110 |
Why?
| | Genetic Variation | 1 | 2018 | 926 | 0.110 |
Why?
| | GA-Binding Protein Transcription Factor | 2 | 2003 | 5 | 0.110 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 287 | 0.110 |
Why?
| | Nitriles | 2 | 2010 | 155 | 0.110 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 87 | 0.100 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 3 | 2003 | 18 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2009 | 180 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-ets | 3 | 2003 | 51 | 0.100 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 369 | 0.100 |
Why?
| | Tumor Burden | 1 | 2012 | 274 | 0.100 |
Why?
| | Protein Binding | 3 | 2009 | 1975 | 0.100 |
Why?
| | Cytostatic Agents | 1 | 2009 | 6 | 0.090 |
Why?
| | Rats | 3 | 2006 | 5392 | 0.090 |
Why?
| | Butadienes | 1 | 2009 | 33 | 0.090 |
Why?
| | Enzyme Activation | 2 | 2009 | 828 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2010 | 827 | 0.080 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 189 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1047 | 0.080 |
Why?
| | Benzamides | 1 | 2009 | 176 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 462 | 0.080 |
Why?
| | Transfection | 4 | 2015 | 888 | 0.080 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 940 | 0.080 |
Why?
| | Indoles | 1 | 2009 | 316 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2874 | 0.070 |
Why?
| | Binding, Competitive | 2 | 2009 | 205 | 0.070 |
Why?
| | Sulfonamides | 1 | 2009 | 445 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2008 | 224 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 306 | 0.070 |
Why?
| | Male | 5 | 2015 | 57801 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 770 | 0.060 |
Why?
| | Sequence Analysis, Protein | 1 | 2003 | 31 | 0.060 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2871 | 0.060 |
Why?
| | Proteomics | 1 | 2009 | 876 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2008 | 2657 | 0.060 |
Why?
| | Transcription Factor Pit-1 | 2 | 2003 | 23 | 0.050 |
Why?
| | Neoplasms | 1 | 2016 | 2179 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2003 | 163 | 0.050 |
Why?
| | Protein Subunits | 1 | 2003 | 211 | 0.050 |
Why?
| | Transcriptional Activation | 2 | 2003 | 348 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 2071 | 0.050 |
Why?
| | RNA, Catalytic | 1 | 2002 | 182 | 0.050 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2001 | 80 | 0.050 |
Why?
| | Aged | 1 | 2019 | 19657 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1323 | 0.050 |
Why?
| | Oligonucleotides | 1 | 2001 | 140 | 0.050 |
Why?
| | Hypoxia | 1 | 2006 | 963 | 0.040 |
Why?
| | Pituitary Neoplasms | 1 | 2001 | 165 | 0.040 |
Why?
| | HeLa Cells | 1 | 2001 | 583 | 0.040 |
Why?
| | Toxicology | 1 | 2019 | 35 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 159 | 0.040 |
Why?
| | Middle Aged | 1 | 2019 | 27617 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 34 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 28 | 0.040 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 35 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 381 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 46 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 43 | 0.040 |
Why?
| | Oncogenes | 1 | 2018 | 111 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2018 | 258 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 175 | 0.040 |
Why?
| | Trans-Activators | 1 | 1999 | 373 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 134 | 0.040 |
Why?
| | Catalysis | 1 | 1997 | 295 | 0.040 |
Why?
| | Gene Frequency | 1 | 2018 | 513 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 1999 | 565 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 289 | 0.030 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 124 | 0.030 |
Why?
| | User-Computer Interface | 1 | 2016 | 163 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 389 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2009 | 371 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2016 | 151 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1166 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 52 | 0.030 |
Why?
| | Microsatellite Repeats | 1 | 2014 | 143 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1223 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 468 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 80 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 588 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 95 | 0.030 |
Why?
| | DNA | 1 | 1999 | 1388 | 0.030 |
Why?
| | Disease Progression | 1 | 2018 | 2490 | 0.020 |
Why?
| | Cell Movement | 1 | 2015 | 896 | 0.020 |
Why?
| | Oleanolic Acid | 1 | 2010 | 9 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1541 | 0.020 |
Why?
| | Autophagy | 1 | 2014 | 315 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2014 | 688 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.020 |
Why?
| | Sulfones | 1 | 2010 | 98 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2009 | 100 | 0.020 |
Why?
| | Serum | 1 | 2009 | 63 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2009 | 439 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1194 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2009 | 308 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4077 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9342 | 0.020 |
Why?
| | Suppression, Genetic | 1 | 2003 | 25 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2566 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 96 | 0.010 |
Why?
| | Cell Extracts | 1 | 2002 | 17 | 0.010 |
Why?
| | Allosteric Regulation | 1 | 2002 | 85 | 0.010 |
Why?
| | United States | 1 | 2018 | 12555 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 536 | 0.010 |
Why?
| | Cell-Free System | 1 | 1999 | 49 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 1999 | 52 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 2002 | 670 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2159 | 0.010 |
Why?
| | Time Factors | 1 | 2002 | 6412 | 0.010 |
Why?
|
|
Schweppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|